Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TLR2 | O60603 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28292932 | 0.96 | TDP1 (0.40) | TDP1LMNAMAPTTSHRHTT | |
| SCHEMBL7651937 | 0.90 | TDP1 (0.43) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL22360502 | 0.82 | TDP1 (0.39) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL8862807 | 0.82 | TDP1 (0.39) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL7651938 | 0.82 | MAPT (0.40) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL1401407 | 0.82 | MEN1 (0.44) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL1401325 | 0.82 | MEN1 (0.44) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL25868407 | 0.81 | TDP1 (0.57) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL12588874 | 0.80 | TSHR (0.43) | TDP1LMNAMAPTTSHRMEN1 | |
| SCHEMBL8100476 | 0.80 | TDP1 (0.40) | TDP1LMNAMAPTTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6197299-B1 | TARGET CELL IS CONTACTED WITH A TARGET CELL LYSIS EFFECTIVE AMOUNT OF A SOLUBLE MONOCLONAL ANTIBODY OR FRAGMENT CONJUGATE COVALENTLY LINKED BY PEPTIDE BOND LINKAGE TO A SUPERANTIGEN FOR THE LYSIS OF A TARGET CELL BY ASSISTANCE OF LYMPHOCYTES | PHARMACIA & UPJOHN AB (SE) | 2001-03-06 | — | — | US | disclosed |
| US-5858363-A | WHEREIN ANTIBODY IS SPECIFIC FOR CELL SURFACE STRUCTURE AND SUPERANTIGEN IS CAPABLE OF ACTIVATING CYTOTOXIC T-CELLS | PHARMACIA & UPJOHN AB (IT) | 1999-01-12 | — | — | US | disclosed |
| EP-0610179-B1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION | PHARMACIA AB (SE) | 1996-10-16 | — | — | EP | disclosed |
| EP-0610179-A1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION. | KABI PHARMACIA AB (SE) | 1994-08-17 | — | — | EP | disclosed |
| EP-0540612-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | Pharmacia AB (SE) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001470-A1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |
| WO-1992001474-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |